This gene encodes the coagulation factor XIII A subunit. Coagulation factor XIII is the last zymogen to become activated in the blood coagulation cascade. Plasma factor XIII is a heterotetramer composed of 2 A subunits and 2 B subunits. The A subunits have catalytic function, and the B subunits do not have enzymatic activity and may serve as plasma carrier molecules. Platelet factor XIII is comprised only of 2 A subunits, which are identical to those of plasma origin. Upon cleavage of the activation peptide by thrombin and in the presence of calcium ion, the plasma factor XIII dissociates its B subunits and yields the same active enzyme, factor XIIIa, as platelet factor XIII. This enzyme acts as a transglutaminase to catalyze the formation of gamma-glutamyl-epsilon-lysine crosslinking between fibrin molecules, thus stabilizing the fibrin clot. It also crosslinks alpha-2-plasmin inhibitor, or
Catalog No
L0206
Reactivity
Human, Rat, Mouse
Applications
WB, ELISA
Modification
Cleaved Specific
Source
Polyclonal Rabbit
Dilution
Western Blot: 1/500 - 1/2000. ELISA: 1/20000. Not yet tested in other applications.
Purification
The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
Concentration
1 mg/ml
Storage and Stability
-20°C/1 year
Other Name
F13A1; F13A; Coagulation factor XIII A chain; Coagulation factor XIIIa; Protein-glutamine gamma-glutamyltransferase A chain; Transglutaminase A chain
Molecular Weight (Da)
83267
Gene Name
F13A1
Protein Name
Coagulation factor XIII A chain
Human Gene ID
2162
Human Swiss Prot No.
P00488
Immunogen
The antiserum was produced against synthesized peptide derived from human FA13A. AA range:20-69
Specificity
Cleaved-Factor XIIIa (G39) Polyclonal Antibody detects endogenous levels of fragment of activated Factor XIIIa protein resulting from cleavage adjacent to G39.
Formulation
Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
Western blot analysis of lysates from Jurkat cells, treated with etoposide 25uM 24h, using FA13A (Cleaved-Gly39) Antibody. The lane on the right is blocked with the synthesized peptide.
